at Benzinga.com (Jan 13, 2015)
Amarin (AMRN -0.6%) lags the general market after being being given a less than enthusiastic initiation by analysts at Chardan Capital Markets with a Hold rating and a price target of $8.50 a share. The firm says that the chance for a strategic deal over the near-term is low, and Vascepa faces risks of a tepid debut.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Nov 19, 2014)
at CNBC.com (Feb 28, 2014)
at MarketWatch.com (Jan 21, 2014)
at CNBC.com (Oct 17, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs